pH and Redox Dual-Responsive Nanoparticle with Enhanced Dendritic Cell Maturation for Cancer Therapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Type I interferons (IFNs) are crucial for T cell activation via dendritic cells (DCs).
• Chemotherapy combined with metalloimmunotherapy can induce IFNs through the cGAS-STING pathway.
• Chemotherapy often depletes DCs, hindering anti-tumor immunity, and optimal ratios for DC activation are unknown.

Purpose of the Study:

• To investigate an optimal ratio of chemotherapeutic agents and metal for maximal DC maturation and anti-cancer activity.
• To develop a nanoparticle that prevents DC depletion and activates the cGAS-STING pathway.
• To enhance IFN production and DC maturation for improved cancer immunotherapy.

Main Methods:

• Designed a pH and redox dual-responsive nanoparticle, MnO2@BSA@DOX (MD), with varying DOX to manganese ratios.
• Evaluated MD's selectivity, DC maturation, depletion, and cGAS-STING pathway activation in cancer cells and DCs.
• Assessed MD's anti-cancer efficacy, including tumor suppression, survival rates, and systemic toxicity.

Main Results:

• The 1:1 ratio of MD demonstrated the highest DC maturation without significant depletion.
• MD selectively targeted cancer cells via tumor microenvironment pH and intracellular redox reactions.
• MD induced cancer cell apoptosis, cGAS-STING activation, enhanced DC phagocytosis, and superior tumor suppression.

Conclusions:

• An optimal 1:1 ratio of MnO2@BSA@DOX nanoparticles promotes DC maturation and anti-cancer activity while preserving DC populations.
• This nanoparticle formulation effectively activates the cGAS-STING pathway, boosts IFN production, and enhances anti-tumor immunity.
• The developed MD nanoparticles show significant potential as a safe and effective therapeutic agent for cancer treatment.